May 30, 2025
Combining rapamycin with the anti-cancer drug trametinib produced a synergistic effect and robust life extension in a new study [1]. A multi-node approach Rapamycin, which was first widely used as an immunosuppressant for transplant patients and is also used in oncology, is considered one of the most powerful geroprotectors. In the "gold standard" Interventions Testing...
August 01, 2024
Combining rapamycin and trametinib seemed to have a cumulative effect in both sexes but mostly in females [1]. These results are probably due to a reduction in both cancer and inflammation. A winning combo The idea that combination treatments are the future of life extension is gaining traction. As aging is a complex phenomenon, a...
